BECLOVENT
LOE ApproachingNDAINHALATIONAEROSOL, METERED
Approved
Jun 1980
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 10h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BECLOVENT is a metered-dose aerosol inhaled corticosteroid approved by GSK in 1980 for respiratory inflammatory conditions. The drug delivers a small-molecule corticosteroid directly to the lungs via inhalation, reducing airway inflammation and improving breathing. It represents a foundational therapy in inhaled steroid treatment.
LOE Approaching
Product is in advanced lifecycle stage with moderate competitive pressure (30%), indicating smaller brand team focus on retention and lifecycle management rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Career opportunities in BECLOVENT are limited and defensive in nature, focused on market retention and managed decline as LOE approaches. Professionals joining this team should expect portfolio transition planning and skills development in generic/lifecycle management rather than growth-driven innovation.
Brand ManagerProduct Manager
Worked on BECLOVENT at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.